Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.

DuPont climbed as it said strength in electronics, healthcare and water end-markets outweighed the hit from import duties.

UnitedHealth is deeply undervalued, trading at low P/E and P/FCF multiples despite long-term growth potential and a wide ...

U.S. commercial revenue skyrocketed 93% year over year on phenomenal demand for the company's artificial intelligence ...

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

These 10 stocks could mint the next wave of millionaires › SBA Communications (NASDAQ:SBAC), a leading owner and operator of wireless communications towers, announced results for the second quarter on ...

Archer-Daniels-Midland posted its lowest second-quarter profit in five years on Tuesday as U.S. trade upheaval and uncertainty around biofuel policies slowed sales and crimped trading and crop ...

Keppel Infrastructure Trust's ( SGX:A7RU ) robust earnings report didn't manage to move the market for its stock.

The chemical-and-materials maker on Tuesday forecast sales around $12.85 billion and adjusted earnings per share around $4.40. The Wilmington, Del., company previously guided for sales between $12.8 ...

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more expensive when valued on FCF -- about 103 times. These might be acceptable ...